Financial Reporting - GENFIT filed its 2022 Universal Registration Document and Annual Report on Form 20-F with the AMF and SEC, respectively, for the year ended December 31, 2022[1]. - The 2022 Universal Registration Document includes the annual financial report and management report, among other key documents[5]. - The 2022 reports are publicly available for free on GENFIT's website and the AMF and SEC websites[2]. Company Focus and Pipeline - GENFIT is focused on improving the lives of patients with severe liver diseases characterized by high unmet medical needs[3]. - The company has a diversified pipeline covering six therapeutic areas, including acute on-chronic liver failure and hepatic encephalopathy, with programs at various development stages[4]. - The company is engaged in research and development of innovative therapeutic and diagnostic solutions, particularly for NASH and ACLF[4]. Shareholder Information - IPSEN holds 8% of GENFIT's share capital, making it one of the largest shareholders[6]. Risks and Forward-Looking Statements - Forward-looking statements indicate potential risks related to R&D, regulatory approvals, and market conditions that could impact future performance[6]. International Presence and Integration - GENFIT's facilities are located in Lille, Paris, Zurich, and Cambridge, MA, indicating a strong international presence[6]. - The company emphasizes its commitment to integrating assets from acquisitions, such as Versantis, to enhance its development capabilities[6].
Genfit(GNFT) - 2022 Q4 - Annual Report